A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users

Michael B Drummond, Jacquie Astemborski, Allison A Lambert, Scott Goldberg, Maxine L Stitzer, Christian A Merlo, Cynthia S Rand, Robert A Wise, Gregory D Kirk, Michael B Drummond, Jacquie Astemborski, Allison A Lambert, Scott Goldberg, Maxine L Stitzer, Christian A Merlo, Cynthia S Rand, Robert A Wise, Gregory D Kirk

Abstract

Background: Even after quitting illicit drugs, tobacco abuse remains a major cause of morbidity and mortality in former injection drug users. An important unmet need in this population is to have effective interventions that can be used in the context of community based care. Contingency management, where a patient receives a monetary incentive for healthy behavior choices, and incorporation of individual counseling regarding spirometric "lung age" (the age of an average healthy individual with similar spirometry) have been shown to improve cessation rates in some populations. The efficacy of these interventions on improving smoking cessation rates has not been studied among current and former injection drug users.

Methods: In a randomized, factorial design study, we recruited 100 active smokers from an ongoing cohort study of current and former injection drug users to assess the impact of contingency management and spirometric lung age on smoking cessation. The primary outcome was 6-month biologically-confirmed smoking cessation comparing contingency management, spirometric lung age or both to usual care. Secondary outcomes included differences in self-reported and biologically-confirmed cessation at interim visits, number of visits attended and quit attempts, smoking rates at interim visits, and changes in Fagerstrom score and self-efficacy.

Results: Six-month biologically-confirmed smoking cessations rates were 4% usual care, 0% lung age, 14% contingency management and 0% for combined lung age and contingency management (p = 0.13). There were no differences in secondary endpoints comparing the four interventions or when pooling the lung age groups. Comparing contingency management to non-contingency management, 6-month cessation rates were not different (7% vs. 2%; p = 0.36), but total number of visits with exhaled carbon monoxide-confirmed abstinence were higher for contingency management than non-contingency management participants (0.38 vs. 0.06; p = 0.03), and more contingency management participants showed reduction in their Fagerstrom score from baseline to follow-up (39% vs. 18%; p = 0.03).

Conclusions: While lung age appeared ineffective, contingency management was associated with more short-term abstinence and lowered nicotine addiction. Contingency management may be a useful tool in development of effective tobacco cessation strategies among current and former injection drug users.

Trial registration: Clinicaltrials.gov NCT01334736 (April 12, 2011).

Figures

Figure 1
Figure 1
Study screening, randomization and follow-up.
Figure 2
Figure 2
Relative effect of contingency management on six-month study outcomes. The figure displays the difference in the percent of participants reporting 6-month outcomes comparing contingency management to non-contingency management interventions. Center points represent the estimated difference in proportions with bars showing 95% confidence intervals. Vertical line represents no difference in proportion between interventions.
Figure 3
Figure 3
Relative effect of contingency management on cumulative study outcomes. Number of Study Visits. The displays the difference in number of cumulative study visits for the stated outcome, comparing contingency management to non-contingency management interventions. Center points represent the estimated mean difference in study visits with bars showing 95% confidence intervals. Vertical line represents no difference in number of visits between interventions.

References

    1. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. AIDS Educ Prev. 2009;21(3 Suppl):28–39. doi: 10.1521/aeap.2009.21.3_supp.28.
    1. Darke S, Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend. 1995;39(3):231–235. doi: 10.1016/0376-8716(95)01171-9.
    1. Sullivan MA, Covey LS. Current perspectives on smoking cessation among substance abusers. Curr Psychiatry Rep. 2002;4(5):388–396. doi: 10.1007/s11920-002-0087-5.
    1. Kirk GD, Merlo CA. HIV infection in the etiology of lung cancer: confounding, causality, and consequences. Proc Am Thorac Soc. 2011;8(3):326–332. doi: 10.1513/pats.201009-061WR.
    1. Clemmey P, Brooner R, Chutuape MA, Kidorf M, Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend. 1997;44(2–3):123–132. doi: 10.1016/S0376-8716(96)01331-2.
    1. Dell JL, Whitman S, Shah AM, Silva A, Ansell D. Smoking in 6 diverse Chicago communities–a population study. Am J Public Health. 2005;95(6):1036–1042. doi: 10.2105/AJPH.2004.051169.
    1. Barbeau EM, Krieger N, Soobader MJ. Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000. Am J Public Health. 2004;94(2):269–278. doi: 10.2105/AJPH.94.2.269.
    1. Honjo K, Tsutsumi A, Kawachi I, Kawakami N. What accounts for the relationship between social class and smoking cessation? Results of a path analysis. Soc Sci Med. 2006;62(2):317–328. doi: 10.1016/j.socscimed.2005.06.011.
    1. Brook JS, Brook DW, Zhang C. Psychosocial predictors of nicotine dependence in Black and Puerto Rican adults: a longitudinal study. Nicotine Tob Res. 2008;10(6):959–967. doi: 10.1080/14622200802092515.
    1. Kanjilal S, Gregg EW, Cheng YJ, Zhang P, Nelson DE, Mensah G, Beckles GL. Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971–2002. Arch Intern Med. 2006;166(21):2348–2355. doi: 10.1001/archinte.166.21.2348.
    1. Clarke JG, Stein MD, McGarry KA, Gogineni A. Interest in smoking cessation among injection drug users. Am J Addict. 2001;10(2):159–166. doi: 10.1080/105504901750227804.
    1. Stark MJ, Campbell BK. Cigarette smoking and methadone dose levels. Am J Drug Alcohol Abuse. 1993;19(2):209–217. doi: 10.3109/00952999309002681.
    1. Frosch DL, Shoptaw S, Nahom D, Jarvik ME. Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Exp Clin Psychopharmacol. 2000;8(1):97–103. doi: 10.1037/1064-1297.8.1.97.
    1. Higgins ST. Contingency management in substance abuse treatment. New York: Guilford Press; 2007.
    1. Vlahov D, Strathdee S. The bottom line on cash incentives with drug users. Addiction. 2009;104(5):796–797. doi: 10.1111/j.1360-0443.2009.02590.x.
    1. Strong Kinnaman JE, Slade E, Bennett ME, Bellack AS. Examination of contingency payments to dually-diagnosed patients in a multi-faceted behavioral treatment. Addict Behav. 2007;32(7):1480–1485. doi: 10.1016/j.addbeh.2006.10.003.
    1. Iguchi MY, Stitzer ML, Bigelow GE, Liebson IA. Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend. 1988;22(1–2):1–7. doi: 10.1016/0376-8716(88)90030-0.
    1. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol. 1992;60(6):927–934. doi: 10.1037/0022-006X.60.6.927.
    1. Kidorf M, King VL, Neufeld K, Peirce J, Kolodner K, Brooner RK. Improving substance abuse treatment enrollment in community syringe exchangers. Addiction. 2009;104(5):786–795. doi: 10.1111/j.1360-0443.2009.02560.x.
    1. Dunn KE, Sigmon SC, Reimann EF, Badger GJ, Heil SH, Higgins ST. A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. Exp Clin Psychopharmacol. 2010;18(1):37–50. doi: 10.1037/a0018649.
    1. Dunn KE, Sigmon SC, Thomas CS, Heil SH, Higgins ST. Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: a pilot study. J Appl Behav Anal. 2008;41(4):527–538. doi: 10.1901/jaba.2008.41-527.
    1. Alessi SM, Petry NM, Urso J. Contingency management promotes smoking reductions in residential substance abuse patients. J Appl Behav Anal. 2008;41(4):617–622. doi: 10.1901/jaba.2008.41-617.
    1. Volpp KG, Gurmankin Levy A, Asch DA, Berlin JA, Murphy JJ, Gomez A, Sox H, Zhu J, Lerman C. A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomarkers Prev. 2006;15(1):12–18. doi: 10.1158/1055-9965.EPI-05-0314.
    1. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, Galvin R, Zhu J, Wan F, DeGuzman J, Corbett E, Weiner J, Audrain-McGovern J. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009;360(7):699–709. doi: 10.1056/NEJMsa0806819.
    1. Morris JF, Temple W. Spirometric "lung age" estimation for motivating smoking cessation. Prev Med. 1985;14(5):655–662. doi: 10.1016/0091-7435(85)90085-4.
    1. Lipkus IM, Prokhorov AV. The effects of providing lung age and respiratory symptoms feedback on community college smokers' perceived smoking-related health risks, worries and desire to quit. Addict Behav. 2007;32(3):516–532. doi: 10.1016/j.addbeh.2006.05.018.
    1. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, Solomon L, Polk BF. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.
    1. Marshall MM, Kirk GD, Caporaso NE, McCormack MC, Merlo CA, Hague JC, Mehta SH, Engels EA. Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav. 2011;36(1–2):61–67. doi: 10.1016/j.addbeh.2010.08.022.
    1. Drummond MB, Kirk GD, McCormack MC, Marshall MM, Ricketts EP, Mehta SH, Wise RA, Merlo CA. HIV and COPD: impact of risk behaviors and diseases on quality of life. Qual Life Res. 2010;19(9):1295–1302. doi: 10.1007/s11136-010-9701-x.
    1. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, Lyles CM, Nelson KE, Smith D, Holmberg S, Farzadegan H. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA. 1998;279(1):35–40. doi: 10.1001/jama.279.1.35.
    1. Shoptaw S, Jarvik ME, Ling W, Rawson RA. Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addict Behav. 1996;21(3):409–412. doi: 10.1016/0306-4603(95)00066-6.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J for the ATS/ERS Task Force Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805.
    1. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–187. doi: 10.1164/ajrccm.159.1.9712108.
    1. Deveci SE, Deveci F, Acik Y, Ozan AT. The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir Med. 2004;98(6):551–556. doi: 10.1016/j.rmed.2003.11.018.
    1. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390–395. doi: 10.1037/0022-006X.51.3.390.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–1127. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. Wagenknecht LE, Burke GL, Perkins LL, Haley NJ, Friedman GD. Misclassification of smoking status in the CARDIA study: a comparison of self-report with serum cotinine levels. Am J Public Health. 1992;82(1):33–36. doi: 10.2105/AJPH.82.1.33.
    1. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101(2):192–203. doi: 10.1111/j.1360-0443.2006.01311.x.
    1. Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther. 2008;83(4):644–647. doi: 10.1038/sj.clpt.6100508.
    1. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000;58(1–2):55–66. doi: 10.1016/S0376-8716(99)00068-X.
    1. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546–1560. doi: 10.1111/j.1360-0443.2006.01581.x.
    1. Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, Schwartz M, Krasnansky J, Pencer E, Silva-Vazquez L, Kirby KC, Royer-Malvestuto C, Roll JM, Cohen A, Copersino ML, Kolodner K, Li R. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry. 2006;63(2):201–208. doi: 10.1001/archpsyc.63.2.201.
    1. Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC, Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE, Macdonald M, Liebert M, Rader L, Burns R, DiMaria J, Copersino M, Stabile PQ, Kolodner K, Li R. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry. 2005;62(10):1148–1156. doi: 10.1001/archpsyc.62.10.1148.
    1. Stitzer M. Contingency management and the addictions. Addiction. 2006;101(11):1536–1537. doi: 10.1111/j.1360-0443.2006.01644.x.
    1. Stitzer ML, Polk T, Bowles S, Kosten T. Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend. 2010;107(1):76–79. doi: 10.1016/j.drugalcdep.2009.09.006.
    1. Sorensen JL, Masson CL, Delucchi K, Sporer K, Barnett PG, Mitsuishi F, Lin C, Song Y, Chen T, Hall SM. Randomized trial of drug abuse treatment-linkage strategies. J Consult Clin Psychol. 2005;73(6):1026–1035. doi: 10.1037/0022-006X.73.6.1026.
    1. Haukoos JS, Witt MD, Coil CJ, Lewis RJ. The effect of financial incentives on adherence with outpatient human immunodeficiency virus testing referrals from the emergency department. Acad Emerg Med. 2005;12(7):617–621. doi: 10.1111/j.1553-2712.2005.tb00916.x.
    1. Thornton R. The Demand for, and Impact of Learning HIV Status. Am Econ Rev. 2008;98(5):1829–1863. doi: 10.1257/aer.98.5.1829.
    1. Rogers RE, Higgins ST, Silverman K, Thomas CS, Badger GJ, Bigelow G, Stitzer M. Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers. Psychol Addict Behav. 2008;22(4):544–550. doi: 10.1037/0893-164X.22.4.544.
    1. Schroeder JR, Epstein DH, Umbricht A, Preston KL. Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav. 2006;31(5):868–879. doi: 10.1016/j.addbeh.2005.07.009.
    1. Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E, Larkins S, Veniegas RC, Freese TE, Hucks-Ortiz C. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78(2):125–134. doi: 10.1016/j.drugalcdep.2004.10.004.
    1. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(5):455–459. doi: 10.1097/00042560-199604150-00005.
    1. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88(1):54–63. doi: 10.1016/j.drugalcdep.2006.09.019.
    1. Petry NM, Weinstock J, Alessi SM, Lewis MW, Dieckhaus K. Group-based randomized trial of contingencies for health and abstinence in HIV patients. J Consult Clin Psychol. 2010;78(1):89–97. doi: 10.1037/a0016778.
    1. Rosen MI, McMahon TJ, Rosenheck R. Does assigning a representative payee reduce substance abuse? Drug Alcohol Depend. 2007;86(2–3):115–122. doi: 10.1016/j.drugalcdep.2006.05.026.
    1. Simoni JM, Chen WT, Huh D, Fredriksen-Goldsen KI, Pearson C, Zhao H, Shiu CS, Wang X, Zhang F. A Preliminary Randomized Controlled Trial of a Nurse-Delivered Medication Adherence Intervention Among HIV-Positive Outpatients Initiating Antiretroviral Therapy in Beijing, China. AIDS Behav. 2010;15(5):919–929. doi: 10.1007/s10461-010-9828-3.
    1. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598–600. doi: 10.1136/bmj.39503.582396.25.
    1. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q. 1984;11(1):1–47. doi: 10.1177/109019818401100101.
    1. Weinstein ND, Lyon JE, Sandman PM, Cuite CL. Experimental evidence for stages of health behavior change: the precaution adoption process model applied to home radon testing. Health Psychol. 1998;17(5):445–453. doi: 10.1037/0278-6133.17.5.445.
    1. Rogers RW. Cognitive and physiological processes in fear appeals and the attitude change: A revised theory of protection motivation. In: Petty JTCRE, editor. Social psychosocialphysiology: A sourcebook. New York: Guilford; 1983. pp. 153–176.
    1. Hansen WB, Collins LM, Johnson CA, Graham JW. Self-initiated smoking cessation among high school students. Addict Behav. 1985;10(3):265–271. doi: 10.1016/0306-4603(85)90007-3.
    1. Milam JE, Sussman S, Ritt-Olson A, Dent CW. Perceived invulnerability and cigarette smoking among adolescents. Addict Behav. 2000;25(1):71–80. doi: 10.1016/S0306-4603(99)00034-9.
    1. Romer D, Jamieson P. Do adolescents appreciate the risks of smoking? Evidence from a national survey. J Adolesc Health. 2001;29(1):12–21. doi: 10.1016/S1054-139X(01)00209-9.
    1. Rose JS, Chassin L, Presson CC, Sherman SJ. Prospective predictors of quit attempts and smoking cessation in young adults. Health Psychol. 1996;15(4):261–268. doi: 10.1037/0278-6133.15.4.261.
    1. Vidrine DJ, Fletcher FE, Danysh HE, Marani S, Vidrine JI, Cantor SB, Prokhorov AV. A randomized controlled trial to assess the efficacy of an interactive mobile messaging intervention for underserved smokers: Project ACTION. BMC Public Health. 2012;12:696. doi: 10.1186/1471-2458-12-696.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj